These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 22085980)
1. NF-κB signaling in prostate cancer: a promising therapeutic target? Jain G; Cronauer MV; Schrader M; Möller P; Marienfeld RB World J Urol; 2012 Jun; 30(3):303-10. PubMed ID: 22085980 [TBL] [Abstract][Full Text] [Related]
2. NF-κB signaling promotes castration-resistant prostate cancer initiation and progression. Thomas-Jardin SE; Dahl H; Nawas AF; Bautista M; Delk NA Pharmacol Ther; 2020 Jul; 211():107538. PubMed ID: 32201312 [TBL] [Abstract][Full Text] [Related]
3. Androgen receptor footprint on the way to prostate cancer progression. Hodgson MC; Bowden WA; Agoulnik IU World J Urol; 2012 Jun; 30(3):279-85. PubMed ID: 21927983 [TBL] [Abstract][Full Text] [Related]
4. Androgen receptor dampens tissue factor expression via nuclear factor-κB and early growth response protein 1. Hoesel B; Mussbacher M; Dikorman B; Salzmann M; Assinger A; Hell L; Thaler J; Basílio J; Moser B; Resch U; Paar H; Mackman N; Schmid JA J Thromb Haemost; 2018 Apr; 16(4):749-758. PubMed ID: 29427323 [TBL] [Abstract][Full Text] [Related]
5. NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Austin DC; Strand DW; Love HL; Franco OE; Grabowska MM; Miller NL; Hameed O; Clark PE; Matusik RJ; Jin RJ; Hayward SW Prostate; 2016 Aug; 76(11):1004-18. PubMed ID: 27197599 [TBL] [Abstract][Full Text] [Related]
6. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Jin RJ; Lho Y; Connelly L; Wang Y; Yu X; Saint Jean L; Case TC; Ellwood-Yen K; Sawyers CL; Bhowmick NA; Blackwell TS; Yull FE; Matusik RJ Cancer Res; 2008 Aug; 68(16):6762-9. PubMed ID: 18701501 [TBL] [Abstract][Full Text] [Related]
7. Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer. Nguyen DP; Li J; Yadav SS; Tewari AK BJU Int; 2014 Aug; 114(2):168-76. PubMed ID: 24215139 [TBL] [Abstract][Full Text] [Related]
8. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508 [TBL] [Abstract][Full Text] [Related]
9. Bakuchiol exhibits anti-metastasis activity through NF-κB cross-talk signaling with AR and ERβ in androgen-independent prostate cancer cells PC-3. Miao L; Yun X; Tao R; Wang Y; Fan G; Zhu Y; Cai T; Zhu Z; Yan C; Gao X J Pharmacol Sci; 2018 Sep; 138(1):1-8. PubMed ID: 30236540 [TBL] [Abstract][Full Text] [Related]
10. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070 [TBL] [Abstract][Full Text] [Related]
11. Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer. McCarty MF; Hejazi J; Rastmanesh R Integr Cancer Ther; 2014 Sep; 13(5):386-95. PubMed ID: 24867960 [TBL] [Abstract][Full Text] [Related]
12. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603 [TBL] [Abstract][Full Text] [Related]
13. From pathogenesis to prevention of castration resistant prostate cancer. Bonkhoff H; Berges R Prostate; 2010 Jan; 70(1):100-12. PubMed ID: 19760632 [TBL] [Abstract][Full Text] [Related]
14. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer. Shiota M; Yokomizo A; Naito S Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046 [TBL] [Abstract][Full Text] [Related]
15. Auranofin lethality to prostate cancer includes inhibition of proteasomal deubiquitinases and disrupted androgen receptor signaling. Liu N; Guo Z; Xia X; Liao Y; Zhang F; Huang C; Liu Y; Deng X; Jiang L; Wang X; Liu J; Huang H Eur J Pharmacol; 2019 Mar; 846():1-11. PubMed ID: 30639309 [TBL] [Abstract][Full Text] [Related]
17. Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Lee SO; Lou W; Nadiminty N; Lin X; Gao AC Prostate; 2005 Jul; 64(2):160-7. PubMed ID: 15678501 [TBL] [Abstract][Full Text] [Related]
18. Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review. Kim TJ; Lee YH; Koo KC Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33805919 [TBL] [Abstract][Full Text] [Related]